May, 12 2026
Two scientific presentations will highlight our non-invasive ultrasound therapy Valvosoft®, contributing to ongoing discussions on the management of aortic stenosis.
Programme highlights:
🫀 Non-invasive ultrasound therapy using Valvosoft®: a new way to treat moderate aortic stenosis, presented by A. Latib (Montefiore Medical Center, New York)
📅 May 19, 2026 | 🕒 12:00 – 13:00
📍 AI Lab – Innovation / CV Pipeline
🫀 Non-invasive ultrasound therapy using Valvosoft®: sub-analysis of retreatments, presented by W.K. Kim (University Hospital Schleswig-Holstein, campus Kiel)
📅 May 20, 2026 | 🕒 11:15 – 12:15
đź“Ť Abstract & Case Corner 2A
✅ Following CE marking of Valvosoft®, the first patients have recently been successfully treated at HEGP (Paris) in April 2026.
These treatments mark an important step in the clinical adoption of non-invasive ultrasound for structural heart interventions.
👉 See you in Paris.
#EuroPCR #Cardiology #MedTech #Innovation #AorticStenosis #StructuralHeart #Valvosoft @AP-HP
